Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037342 | 1.00 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL5101972 | 1.00 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL23527440 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL4535082 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL23527439 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL5712566 | 0.85 | SLC6A4 (0.48) | SLC6A4 | |
| SCHEMBL5652929 | 0.85 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL16692504 | 0.85 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL3489363 | 0.82 | GBA1 (0.48) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL3446697 | 0.82 | GBA1 (0.48) | OPRM1OPRD1OPRK1OPRL1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420667-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-16 | — | — | US | claimed |
| EP-2513061-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2012-10-24 | — | — | EP | claimed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | claimed |
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | claimed |
| EP-2150534-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2010-02-10 | — | — | EP | claimed |
| WO-2009130240-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-10-29 | — | — | WO | claimed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | claimed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | claimed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| WO-2019156929-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2019-08-15 | — | — | WO | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8420667-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-16 | — | — | US | disclosed |
| WO-2009130240-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-10-29 | — | — | WO | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | OPRM1 892/4885OPRD1 318/4885OPRK1 105/4885 |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | OPRM1 4711/4885OPRD1 4678/4885OPRK1 2832/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | OPRM1 4711/4885OPRD1 4678/4885OPRK1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.